

## PRESS RELEASE Stockholm December 20, 2022

### **ADDvise receives order worth USD 1.2 million**

ADDvise Group AB's subsidiary Poly Pharmaceuticals Inc has received an additional order from Cochran Wholesale Pharmaceuticals, a generic pharmaceutical wholesale distributor serving the needs of independent pharmacies across the USA. The order is worth approximately USD 1.2 million. The order consists of delivery of the dietary supplemental Folite, developed and manufactured by Poly Pharmaceuticals. Delivery will take place during Q4 2022.

"We see a strong demand in the US market for generic drugs. Generic drugs are a low-cost alternative to branded drugs. Macroeconomic headwinds are pushing customers to find more cost-efficient alternatives", says Rikard Akhtarzand, CEO of ADDvise Group.

### **For further information, please contact:**

Rikard Akhtarzand, CEO  
+46 765-25 90 71  
rikard.akhtarzand@addvisigroup.se

### **Important information:**

*This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on December 20, 2022, at 20:40 CET.*

### **About ADDvise Group**

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expanding the business – both geographically and product-wise. ADDvise Group's shares are listed on Nasdaq First North Premier Growth Market and Mangold Fondkommission AB is the Company's Certified Adviser. Additional information is available at [www.addvisigroup.com](http://www.addvisigroup.com).